Click here to view the August edition of The Meeting Place
News
This transaction increases BioIVT's global network for collecting high-quality, disease-state biospecimens and extends its capabilities to deliver fresh biospecimens and produce cell products for drug and diagnostic development.
AMSBIO announce RNAdvantage – the first product in a new range of stabilization solutions that provide robust protection for your RNA samples at ambient temperature. Designed to protect and preserve RNA from most tissues, cultured cells, bacteria, and yeast for up to 14-days, RNAdvantage eliminates the traditional costs of flash freezing samples dry-ice shipping and freezer storage.
Leading global drug development consultancy Boyds has added to its team with the appointment of experienced regulatory affairs professional Katherine Bowen in response to a rise in demand for its specialist regulatory services.
With more than 14 years’ experience in regulatory affairs across both mid to large pharma and consultancies, Katherine joins Boyds as Senior Director of Regulatory Affairs.
• Stevenage Bioscience Catalyst is leading the way by introducing the Warp It recycling scheme
• The online reuse platform will enable occupier companies to donate and receive lab and office equipment, supplies and furniture
• This will reduce costs and carbon footprints for occupiers
Stevenage Bioscience Catalyst (SBC) is the first science park in the UK to sign up to the Warp It reuse platform. The platform enables companies to donate or receive surplus lab and office equipment, supplies and furniture.
VivoSTART GMP-grade leukopaks complement BioIVT’s GMP-grade human AB serum, providing a complete solution for advanced therapy development
BioIVT, a leading provider of biospecimens, research models and services for drug and diagnostic development, today announced the launch of its Good Manufacturing Practice (GMP-) grade VivoSTART™ leukopaks. Leukopaks contain concentrated white blood cells and are used to research and manufacture cell and gene therapies.
Morgan Sindall Construction appointed as sole contractor to deliver Phase 2 of Unity Campus
• 90,000 sq ft of wet laboratory and office space available in 2023 to let as ‘shell & core’ or ‘fully fitted turnkey solution’
• Available as suites from 3,652 sq ft, up to a single-let building of 32,500 sq ft
• First available newly constructed laboratories in the Cambridge cluster
Domainex Ltd., based in Cambridge UK, is a leading provider of integrated drug discovery services. As a result of the work carried out by Domainex during an in-house research programme to identify inhibitors of protein kinases TBK1 and IKK-epsilon, DMXD-011 has been nominated as a preclinical drug candidate. The molecule is orally-bioavailable and highly selective. The recent human ex-vivo data outlined below indicates this drug should be effective in the treatment of interferonopathies such as lupus, Sjögren’s syndrome, and scleroderma.
PRESS RELEASE
New Study Reveals First Genetic Links in ME and Chronic Fatigue Syndrome Paving the Way for New Diagnostics and Drugs
PrecisionLife Reports 14 Genes Associated with ME/CFS at the M.E. Genetics Research Summit in Edinburgh